What is the HAS-BLED scheme? 
The HAS-BLED scheme is a tool used to stratify the risk of bleeding associated with warfarin treatment for atrial fibrillation. It assigns 1 point each for hypertension, abnormal renal or liver function, past stroke, past bleeding history or predisposition, labile INR (ie, poor time in therapeutic range), older age (age >65 years), and use of certain drugs (concomitant antiplatelet or nonsteroidal anti-inflammatory agent use, alcohol abuse). A validation analysis of data from 2293 subjects randomized to idraparinux or vitamin K antagonist therapy showed the HAS-BLED score was moderately predictive (HAS-BLED >2: HR, 1.9 for clinically relevant bleeding; HR, 2.4 for major bleeding). 